PreciseDx Secures $20.7 Million in Series B Funding to Enhance AI-Driven Breast Cancer Risk Assessments

Funding:
PreciseDx has raised $20.7 million in Series B funding, bringing its total funding to $31.5 million.

Investors:
The funding round was led by Eventide Asset Management, with participation from Labcorp, Quest Diagnostics, GenHenn Capital Venture, and existing investors.

Purpose:
The funding will support the expanded commercialization of PreciseBreast™, an AI-powered risk assessment for breast cancer, and further clinical trials.

Technology:
PreciseDx’s platform uses AI to analyze morphology features from tissue samples, providing patient-specific risk information for more personalized treatment plans.

Impact:
The technology aims to improve breast cancer diagnostics by delivering faster, more accurate data in a cost-efficient manner, leading to better clinical decisions and patient outcomes.

Achievements:
PreciseDx has completed successful validation studies, received regulatory approvals, and published a cost impact study showing significant savings for payers and patients.

Partnerships:
The company has collaborations with institutions like UCLA, COTA, Baptist Health South Florida, and Baylor Scott & White Health.